​

CervoMed Stock (NASDAQ:CRVO)

ForecastRevenueOwnershipFinancialsChart
CervoMed by TradingView

Previous Close

$3.69

52W Range

$2.13 - $13.13

50D Avg

$3.40

200D Avg

$5.74

Market Cap

$32.87M

Avg Vol (3M)

$5.48M

Beta

-4.42

Div Yield

-

CRVO Company Profile

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood–brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies, non-fluent variant primary progressive aphasia, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.

Show More

Industry

Specialty Business Services

Sector

Industrials

Exchange

NASDAQ

ADR

-

Country

US

Employees

15

IPO Date

May 23, 2008

Website

CRVO Performance

CRVO Financial Summary

Dec 25Dec 24Dec 23
Revenue$4.01M--
Operating Income$-28.29M$-18.23M$-7.81M
Net Income$-26.97M$-16.29M$-2.17M
EBITDA$-28.29M$-18.23M$-7.81M
Basic EPS$-2.98$-2.02$-0.82
Diluted EPS$-2.98$-2.02$-0.82

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

TickerCompany
OSTXOS Therapies Incorporated
LITSLite Strategy, Inc.
NRXPNRx Pharmaceuticals, Inc.
ADAGAdagene Inc.
FBIOFortress Biotech, Inc.
NTRBNutriband Inc.
XBITXBiotech Inc.
VTVTvTv Therapeutics Inc.
GANXGain Therapeutics, Inc.
ACETAdicet Bio, Inc.